Co-Diagnostics Q3 revenue rises to $0.3 million; net loss widens to $6.3 million
Co-Diagnostics reported third quarter 2026 revenue of $0.3 million, up from $0.1 million a year earlier, and operating expenses fell 12% to $6.2 million. The net loss widened to $6.3 million from $5.9 million, mainly because the prior-year period included an income tax benefit, and cash was $0.7 million at September 30, 2026. Shortly after quarter end, the company completed a senior secured convertible debt financing with about $2.1 million in initial funding, which shareholders should weigh against the company's limited cash.
Key points
- Q3 2026 revenue was $282,881 versus $145,380 in Q3 2025; cost of revenue of $303,344 exceeded revenue, producing a gross loss of $20,463
- Operating loss narrowed to $6.3 million from $7.0 million; net loss was $6.3 million, or $1.01 per share, versus $5.9 million, or $4.66 per share, a year earlier
- Cash and cash equivalents totaled $0.7 million at September 30, 2026, compared with $11.9 million at December 31, 2025
- After quarter end, a senior secured convertible debt financing with J.J. Astor & Co. provided about $2.1 million in initial funding, with up to $1.0 million more subject to conditions
The filing
Written by AI on Nov 10, 2026, 8:23 AM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.